Copy for the designated Office (DO/US) PCT/SE00/01923

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

NILSSON, Brita
Stockholms Patentbyrå Zacco AB
Box 23101
S-104 35 Stockholm
SUÈDE

Date of mailing (day/month/year) 11 April 2001 (11.04.01)	
Applicant's or agent's file reference 110013401/BN	**IMPORTANT NOTIFICATION**
International application No. PCT/SE00/01923	**International filing date** (day/month/year) 05 October 2000 (05.10.00)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address	State of Nationality	State of Residence
NILSSON, Brita AB Stockholms Patentbyrå, Zacco & Bruhn Box 23101 S-104 35 Stockholm Sweden		
	Telephone No. +46 8 729 95 00	
	Facsimile No. +46 8 31 83 15	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address	State of Nationality	State of Residence
NILSSON, Brita Stockholms Patentbyrå Zacco AB Box 23101 S-104 35 Stockholm Sweden		
	Telephone No. +46 8 729 95 00	
	Facsimile No. +46 8 31 83 15	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office
☐ the International Searching Authority
☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer N. Wagner
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark Office, PCT
2011 South Clark Place Room CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 12 July 2001 (12.07.01)	
International application No. PCT/SE00/01923	**Applicant's or agent's file reference** 110013401/BN
International filing date (day/month/year) 05 October 2000 (05.10.00)	**Priority date** (day/month/year) 07 October 1999 (07.10.99)
Applicant LIGNELL, Åke et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

04 May 2001 (04.05.01)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer Charlotte ENGER
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

12

Applicant's or agent's file reference 110013401/BLN	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/SE00/01923	International filing date *(day/month/year)* 05.10.2000	Priority date *(day/month/year)* 07.10.1999
International Patent Classification (IPC) or national classification and IPC7 A 61 K 31/122, A 61 P 37/00		
Applicant Astacarotene AB et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
04.05.2001	25.01.2002
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88 Telex 17978 PATOREG-S	Authorized officer Anna Sjölund/EÖ Telephone No. 08-782 25 00

Form PCT/IPEA/409 (cover sheet) (January 1998)

INTERNATIONAL PRE[redacted]NARY EXAMINATION REPORT

[redacted]national application No.
PCT/SE00/01923

I. Basis of the report

1. With regard to the **elements** of the international application:*

☒ the international application as originally filed

☐ the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

☐ the claims:
pages _____, as originally filed
pages _____, as amended (together with any statement) under article 19
pages _____, filed with the demand
pages _____, filed with the letter of _____

☐ the drawings:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

☐ the sequence listing part of the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages _____

☐ the claims, Nos. _____

☐ the drawings, sheet/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.*

INTERNATIONAL PRE[redacted]NARY EXAMINATION REPORT

[redacted]national application No.
PCT/SE00/01923

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 9-15

because:

☒ the said international application, or the said claims Nos. 9-15
relate to the following subject matter which does not require an international preliminary examination *(specify)*:

See PCT Rule 67.1.(iv).: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos. _____
are so unclear that no meaningful opinion could be formed *(specify)*:

☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _____

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PR[redacted]INARY EXAMINATION REPORT

[redacted]rnational application No.
PCT/SE00/01923

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-8	YES
	Claims		NO
Inventive step (IS)	Claims	3-8	YES
	Claims	1-2	NO
Industrial applicability (IA)	Claims	1-8	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Following document is discussed in this preliminary examination report:

A. STN International, file CA, acc. no 119:10900, Lipid peroxide-lowering compositions, Jpn. Kokai Tokkyo Koho JP 051224958 A2, 19930521(search report)

Present claims 1-2 relate to physiological conditions defined by reference to their mechanism, namely the suppression of Th1-cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in a patient. The said claims 1-2 are not clear and concise considering which diseases are covered by this expression. The application provides support within the meaning of Article 6 PCT and /or disclosure within the meaning of Article 5 PCT for only a very limited number of such diseases, namely those included in present claim 3 and in the description, page 3.
The applicant´s attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e)PCT).

.../...

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

Further on, the subject matter of claims 1 and 2 is not considered to be fully supported by the description. The experimental data support the effect of astaxanthin (Ast) regarding the treatment of some of the diseases of claim 3. It is already known through A that Ast, a xanthophyll, can be used in compositions for the treatment of diabetes, although in this reference the composition is stated to be anti-oxidant. It has not been shown that Ast is active through the mechanism in claim 1. On the contrary, on page 5, last paragraph, it is held as "likely" that the Th1-mediated response has been suppressed and that there is a shift of the Th1-Th2 balance of the immune response towards the Th2-response. Claims 1 and 2 are therefore not considered to fulfil the requirements of inventive step according to PCT art. 33(3).

In this context, a reference is made to EPO, decision of Technical Board of Appeal , T241/95. In this case it is stressed that in order to make claims clear, which are formulated with a functional definition of the claimed subject-matter, such as the present claims 1-2, means must be available to the skilled person for assessing whether or not an additional condition, not expressly cited in the application, but nevertheless affected by the administration of a xanthophyll is comprised in the scope of claim 1.

Therefore, it is considered that claim 1-8 are novel, but that claims 1-2 do not fulfil the requirements of inventive step, that claims 3-8 fulfil these requirements of inventive step, and that claims 1-8 are industrially applicable.

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Present claims 1-2 relate to physiological conditions defined by reference to their mechanism, namely the suppression of Th1-cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in a patient. The said claims 1-2 are not clear and concise considering which diseases are covered by this expression. The application provides support within the meaning of Article 6 PCT and /or disclosure within the meaning of Article 5 PCT for only a very limited number of such diseases, namely those included in present claim 3 and in the description, page 3.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 00/01923

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/122, A61P 37/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File CA, Chemical abstracts, volume 119, no. 11, 13 September 1993, (Columbus, Ohio, US), Date, Yukio et al: "Lipid peroxide-lowering compositions"; & JP,A2,05124958, 19930521, Heisei --	1-4
X	Nutr Cancer, Volume 26, 1996, Harumi Jyonouchi et al, "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity" page 313 - page 324	1
Y	--	2-15

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search
8 February 2001

Date of mailing of the international search report
14 -02- 2001

Name and mailing address of the ISA:
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Anna Sjölund/EÖ
Telephone No. +46 8 782 25 00

Form PCT ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 00/01923

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Clinical and Diagnostic Laboratory Immunology, Volume 6, No 3, May 1999, Sami T. Azar et al, "Type I (Insulin-Dependent) Diabetes Is a Th1 - and Th2-Mediated Autoimmune Disease" page 306 - page 310 -- --------	2-15

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATION[redacted]EARCH REPORT

Int[redacted]onal application No.
PCT/SE00/01923

Box I **Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9-15
because they relate to subject matter not required to be searched by this Authority, namely:

see next sheet

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II **Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Claims 9-15 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections.

The present invention relates to the use and method of treatment concerning utilization of xanthophylls, e.g. astaxanthin, for suppression of excessive Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.

Background of the invention.

CD4 T lymphocytes can be subdivided into two major subsets - Th1 cells and Th2 cells. These cells release different sets of cytokines that define their distinct actions in immunity. Th1 cells secrete interferon-gamma (IFN-γ) and are mainly involved in activating macrophages and CD8+ cytotoxic T-lymphocytes. Th2 cells secrete the interleukins Il-4, Il-5 and Il-10 and are mainly involved in stimulating B cells to produce antibodies.

There is a balance between the activities of the Th1 and Th2 cells in a normal human body. An excess of Th1 cell activity may be the result of an autoimmune disease, or the result of an ongoing infection. In the normal case, the Th1 cell activity diminishes when the physiological need thereof is reduced. An excess activity is thus seen when the normal reduced level of Th1 cell activity is not achieved as a response to the diminishing presence of the agent that induced the reaction, e.g. the starting point of an autoimmune disease.

Immune modulation aims at altering the balance between different subsets of responding T cells so that damaging responses are suppressed. In many cases autoimmune diseases and intracellular infections are associated with the activation of Th1 cells, which activate macrophages and drive an inflammatory immune response. The drugs currently used to suppress the immune system can be divided into three categories:

1) Powerful anti-inflammatory drugs of the corticosteroid family such as prednisone. Glucocorticoids influence virtually every cellular and humoral mechanism related to inflammation and immune response. However, there are also many adverse effects, including fluid retention, weight gain, diabetes, bone mineral loss and thinning of the skin.

2) Cytotoxic drugs such as azthioprine and cyclophosphamide. Cytotoxic drugs cause immunosuppression by killing dividing cells and they have serious side-effects. The use of these compounds is limited due to a range of toxic effects on tissues that have continuous cell dividing, such as the bone marrow.

3) Cyclosporin A, tacromycin and rapamycin are powerful immunosuppressive agents that interfere with T-cell signaling.

All of these drugs are very broad in their action and inhibit protective functions of the immune system as well as pathological responses that cause tissue injury. Opportunistic infection is therefore a common complication of immune suppressive drugs.

It would be desirable to have an immunosuppressive agent that targets the specific part of the immune response that causes tissue injury. In particular, it would be desirable to obtain a medicament for suppression of harmful, i.e. excessive, Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.

Description of the invention

The present invention provides a medicament for suppression of excessive Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.

One aspect of the invention is directed to the use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.

In a preferred embodiment of the invention the excessive Th1 cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections.

Examples of diseases that cause excessive Th1 cell mediated immune responses are Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin-dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection) and HIV virus infection.

Xanthophylles, including astaxanthin, is a large group of carotenoids containing oxygen in the molecule in addition to carbon and hydrogen. The carotenoids are produced *de novo* by plants, fungi and some bacteria [Johnson E.A. and Schroeder W.A., 1995, Adv In Biochem Engin. Biotechn. 53: 119-178].

In a preferred embodiment of the invention, the type of xanthophyll is astaxanthin, preferably in a form esterified with fatty acids.

In a particularly preferred embodiment the astaxanthin is derived from a natural source, such as a culture of the algae *Haematococcus sp.*, e.g. *Haemotococcus pluvialis.*

The medicament in the invention is preferably an oral preparation, which optionally comprises an oil of food grade and it is suitably presented in separate unit doses.

The medicament may comprise a mixture of different types of xanthophylls or different forms of the same xanthophyll, such as a mixture of synthetic astaxanthin and naturally produced astaxanthin.

The oral preparation may comprise in addition to the xanthophylls auxiliary ingredients that are pharmacologically acceptable inactive or active ingredients, such as flavoring agents, fillers, emulsifiers, etc.

Examples of separate unit doses are tablets, gelatin capsules and predetermined amounts of solutions, e.g. oil solutions, or emulsions, e.g. water-in- oil or oil-in-water emulsions.

Another aspect of the invention is directed to a method of suppressing excessive Th1 cell mediated immune responses and stimulating Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient comprising administration of an Th1 cell response suppressing and Th2 cell response stimulating amount of at least one type of xanthophylls to said patient.

The examples and preferred embodiments described for the use aspect of the invention also apply for this method aspect of the invention.

In particular, excessive Th1 cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections, such as Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn´s disease, Insulin-dependent diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection) and HIV virus infection, and the type of xanthophyll is preferably astaxanthin, particularly in a form esterified with fatty acids, e.g. from a natural source, such as a culture of the algae *Haematococcus sp.*

The daily doses of the active ingredient of the invention will normally be in the range of 0.01 to 10 mg per kg body weight for a human calculated on the amount of astaxanthin, but the actual dose will depend on the immune response of the individual human patient, the reason for suppression of the excessive Th1 cell mediated immune response, such as the type of disease causing the enhanced pathological Th1 cell response, and the recommendations of the manufacturer.

The xanthophyll astaxanthin is commercially produced via culturing of the algae *Haematococcus sp.* by AstaCarotene AB, Gustavsberg, Sweden. It is marketed and sold in Sweden as a dietary supplement

Astaxanthin from other sources, and other xanthophylls as well, are expected to be similarly useful for the purposes of the invention. An advantage of using astaxanthin from

algae is, however, that the astaxanthin exists in a form esterified with fatty acids [Renström B. et al, 1981, Phytochem 20(11) :2561-2564], which esterified astaxanthin thereby is more stable during handling and storage than free astaxanthin.

The naturally produced astaxanthin can be obtained also from fungi and crustaceans, in addition to from algae [Johnson E.A. and Schroeder W.A., ibid].

Case studies

During the last five years reports have been received from patients taking the commercial dietary supplement capsules of the algal meal of *Haematococcus pluvialis,* Astaxin®, containing 4 mg astaxanthin. The daily doses recommended as an antioxidant is one capsule per day. However, 2 – 6 times that dose has been used by some patients without adverse effects. On the contrary, the higher doses have been experienced as beneficial in alleviating symptoms associated with some chronic diseases.

Six patient histories are disclosed more in detail below.

Chron´s disease

Patient 1. Boy, 17 years old, who had suffered from Crohn´s disease for at least four years. He has been treated with anti-inflammatory agents, such as cortisone. He started to take the commercial product Astaxin (two capsules, each containing 4 mg of astaxanthin, per day). In about two months the cortisone treatment was phased out and later on stopped altogether. The patient was asymptomatic for more than a year when he experienced a relapse. He was then received a short-term treatment with cortisone in combination with Astaxin, and the cortisone treatment was again phased out.

Patient 2. Woman, about 50 years of age, who had suffered from Crohn´s disease for a long time. She received treatment with cortisone. Now she has started to take Astaxin in parallel with her steroid medication and she reports that she feels considerably better.

Patient 3. Man, 48 years old, who has suffered from Crohn´s disease for the last 20 years. He has been operated on several times and he has been treated with cortisone. Directly after the last operation he started taking Astaxin (6 capsules per day) and no cortisone. With regard to the circumstances, he has been asymptomatic. He has compared his clinical status after the operation with the status of two other patients who were operated on at the same time and who received conventional treatment with cortisone. In comparison with these two other patients his recovery has been fully equal with theirs, with the positive exception that edema in his colon diminished more quickly than in the two other patients.

Lichen ruber planus.

Patient 4. Woman, more than 70 years of age, who had suffered from the disease for several years. The symptoms of the disease were *inter alia* open wounds which had not healed. She had been treated with anti-inflammatory agents, such as cortisone, for several years, orally and also by injection directly to the local inflammation areas. The treatment has not led to any result. She started to take 4 capsules of Astaxin per day , and after some weeks visible alleviation of the symptoms started to show up. The wounds were healed in slightly more than one month. During this period, the patient herself phased out the cortisone treatment. The dose of Astaxin was lowered to 2 capsules per day when she was asymtomatic. However, the symptoms returned in connection with a common cold. The dose was then increased to 4 capsules per day and the wounds healed again. She says herself that she now feels considerably better.

Psoriasis.

Patient 5. Male, 40 years, who suffers from psoriasis and mainly shows itself in rough skin on the elbows. After treatment with a skin cream enriched with algal meal/astaxanthin (100 mg astaxanthin /kg cream) twice a day for three weeks, the symptoms diminished.

Patient 6. Woman, 45 years old, who suffers from psoriasis and mainly shows itself in rough skin on the elbows. After treatment with a skin cream enriched with algal meal/astaxanthin (100 mg astaxanthin /kg cream) twice a day for three weeks, the symptoms diminished.

Thus, positive reports have been received from several patients suffering from Crohn´s disease, rheumatoid arthritis, psoriasis and lichen planus. All of these diseases are autoimmune diseases which are known to be Th1 cell mediated diseases.

Therefore it is likely that the Th1 mediated response in the patients has been suppressed and that there is a shift of the Th1/Th2 balance of the immune response towards the Th2 response. Further, it is likely that patients suffering from other predominantly Th1 cell mediated diseases would benefit from suppression of excessive Th1 cell responses and stimulation of Th2 cell mediated immune responses during ongoing infection and/or inflammation.

Claims

1. Use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.

2. Use according to claim 1, wherein the excessive Th1 cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections.

3. Use according to claim 2, wherein the disease is Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin-dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection), or HIV virus infection.

4. Use according to any one of claims 1 -3, wherein the type of xanthophyll is astaxanthin.

5. Use according to claim 4, wherein the astaxanthin is in a form esterified with fatty acids.

6. Use according to claim 4 or 5, wherein the astaxanthin is derived from a natural source.

7. Use according to claim 6, wherein the natural source is a culture of the algae *Haematococcus sp.*

8. Use according to any one of the claims 1 - 7, wherein the medicament is an oral preparation.

9. A method of suppressing excessive Th1 cell mediated immune responses and stimulating Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient comprising administration of an Th1 cell response suppressing and Th2 cell response stimulating amount of at least one type of xanthophylls to said patient.

10. The method according to claim 9, wherein the excessive Th1 cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections.

11. The method according to claim 10, wherein the disease is Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin-dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection), or HIV virus infection.

12. The method according to claim 9, wherein the type of xanthophyll is astaxanthin.

13. The method according to claim 12, wherein the astaxanthin is in a form esterified with fatty acids.

14. The method according to claim 12 or 13, wherein the astaxanthin is derived from a natural source.

15. The method according to claim 14, wherein the natural source is a culture of the algae *Haematococcus sp.*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 00/01923

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/122, A61P 37/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File CA, Chemical abstracts, volume 119, no. 11, 13 September 1993, (Columbus, Ohio, US), Date, Yukio et al: "Lipid peroxide-lowering compositions"; & JP,A2,05124958, 19930521, Heisei --	1-4
X	Nutr Cancer, Volume 26, 1996, Harumi Jyonouchi et al, "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity" page 313 - page 324	1
Y	--	2-15

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search
8 February 2001

Date of mailing of the international search report
14 -02- 2001

Name and mailing address of the ISA:
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Anna Sjölund/EÖ
Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 00/01923

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Clinical and Diagnostic Laboratory Immunology, Volume 6, No 3, May 1999, Sami T. Azar et al, "Type I (Insulin-Dependent) Diabetes Is a Th1 - and Th2-Mediated Autoimmune Disease" page 306 - page 310 -- --------	2-15